XCancer

Sintilimab, Bevacizumab Plus Y-90 Selective Internal Radiation Therapy for Patients With Unresectable Intermediate-advanced Hepatocellular Carcinoma: a Prospective, Single-center, Single Arm Trial

Description:

This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).

Sponsor:

Second Affiliated Hospital of Guangzhou Medical University

Phase:

Phase 2

Government Study Link:

NCT06397222 - Click here to see study on

ClinicalTrials.gov